Literature DB >> 17392433

Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C.

Jan M Pestka1, Mirjam B Zeisel, Edith Bläser, Peter Schürmann, Birke Bartosch, Francois-Loïc Cosset, Arvind H Patel, Helga Meisel, Jens Baumert, Sergei Viazov, Kay Rispeter, Hubert E Blum, Michael Roggendorf, Thomas F Baumert.   

Abstract

In contrast to a detailed understanding of antiviral cellular immune responses, the impact of neutralizing antibodies for the resolution of acute hepatitis C is poorly defined. The analysis of neutralizing responses has been hampered by the fact that patient cohorts as well as hepatitis C virus (HCV) strains are usually heterogeneous, and that clinical data from acute-phase and long-term follow-up after infection are not readily available. Using an infectious retroviral HCV pseudoparticle model system, we studied a cohort of women accidentally exposed to the same HCV strain of known sequence. In this single-source outbreak of hepatitis C, viral clearance was associated with a rapid induction of neutralizing antibodies in the early phase of infection. Neutralizing antibodies decreased or disappeared after recovery from HCV infection. In contrast, chronic HCV infection was characterized by absent or low-titer neutralizing antibodies in the early phase of infection and the persistence of infection despite the induction of cross-neutralizing antibodies in the late phase of infection. These data suggest that rapid induction of neutralizing antibodies during the early phase of infection may contribute to control of HCV infection. This finding may have important implications for understanding the pathogenesis of HCV infection and for the development of novel preventive and therapeutic antiviral strategies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17392433      PMCID: PMC1851610          DOI: 10.1073/pnas.0607026104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

Review 1.  Hepatitis C virus entry: molecular biology and clinical implications.

Authors:  Heidi Barth; T Jake Liang; Thomas F Baumert
Journal:  Hepatology       Date:  2006-09       Impact factor: 17.425

2.  Long-term persistence of hepatitis C virus antibodies in a single source outbreak.

Authors:  S Dittmann; M Roggendorf; J Dürkop; M Wiese; B Lorbeer; F Deinhardt
Journal:  J Hepatol       Date:  1991-11       Impact factor: 25.083

3.  High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.

Authors:  Marlène Dreux; Thomas Pietschmann; Christelle Granier; Cécile Voisset; Sylvie Ricard-Blum; Philippe-Emmanuel Mangeot; Zhenyong Keck; Steven Foung; Ngoc Vu-Dac; Jean Dubuisson; Ralf Bartenschlager; Dimitri Lavillette; Francois-Loïc Cosset
Journal:  J Biol Chem       Date:  2006-05-04       Impact factor: 5.157

4.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

5.  Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate.

Authors:  Heidi Barth; Christiane Schafer; Mohammed I Adah; Fuming Zhang; Robert J Linhardt; Hidenao Toyoda; Akiko Kinoshita-Toyoda; Toshihiko Toida; Toin H Van Kuppevelt; Erik Depla; Fritz Von Weizsacker; Hubert E Blum; Thomas F Baumert
Journal:  J Biol Chem       Date:  2003-07-16       Impact factor: 5.157

6.  Antiviral immune responses in gene-targeted mice expressing the immunoglobulin heavy chain of virus-neutralizing antibodies.

Authors:  Lars Hangartner; Beatrice M Senn; Birgit Ledermann; Ulrich Kalinke; Peter Seiler; Etienne Bucher; Raphaël M Zellweger; Katja Fink; Bernhard Odermatt; Kurt Bürki; Rolf M Zinkernagel; Hans Hengartner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

7.  Neutralizing antibody response during acute and chronic hepatitis C virus infection.

Authors:  C Logvinoff; M E Major; D Oldach; S Heyward; A Talal; P Balfe; S M Feinstone; H Alter; C M Rice; J A McKeating
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-25       Impact factor: 11.205

8.  Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles.

Authors:  Mayla Hsu; Jie Zhang; Mike Flint; Carine Logvinoff; Cecilia Cheng-Mayer; Charles M Rice; Jane A McKeating
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-21       Impact factor: 11.205

9.  Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C.

Authors:  Daniel Steinmann; Heidi Barth; Bettina Gissler; Peter Schürmann; Mohammed I Adah; J Tilman Gerlach; Gerd R Pape; Erik Depla; Dirk Jacobs; Geert Maertens; Arvind H Patel; Geneviève Inchauspé; T Jake Liang; Hubert E Blum; Thomas F Baumert
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes.

Authors:  Birke Bartosch; Jens Bukh; Jean-Christophe Meunier; Christelle Granier; Ronald E Engle; William C Blackwelder; Suzanne U Emerson; François-Loïc Cosset; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-14       Impact factor: 11.205

View more
  244 in total

1.  EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.

Authors:  Joachim Lupberger; Mirjam B Zeisel; Fei Xiao; Christine Thumann; Isabel Fofana; Laetitia Zona; Christopher Davis; Christopher J Mee; Marine Turek; Sebastian Gorke; Cathy Royer; Benoit Fischer; Muhammad N Zahid; Dimitri Lavillette; Judith Fresquet; François-Loïc Cosset; S Michael Rothenberg; Thomas Pietschmann; Arvind H Patel; Patrick Pessaux; Michel Doffoël; Wolfgang Raffelsberger; Olivier Poch; Jane A McKeating; Laurent Brino; Thomas F Baumert
Journal:  Nat Med       Date:  2011-04-24       Impact factor: 53.440

Review 2.  Vaccines to prevent infections by oncoviruses.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

3.  Neutralizing antibodies to hepatitis C virus in perinatally infected children followed up prospectively.

Authors:  Jean-Christophe Meunier; Jens Bukh; Giacomo Diaz; Pier-Angelo Tovo; Anna Maria Casadei; Isabella Quinti; Raffaele Iorio; Suzanne Emerson; Robert H Purcell; Patrizia Farci
Journal:  J Infect Dis       Date:  2011-10-17       Impact factor: 5.226

4.  Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals.

Authors:  Haihong Zhu; Flossie Wong-Staal; Haekyung Lee; Andrew Syder; Jeffrey McKelvy; Robert T Schooley; David L Wyles
Journal:  J Infect Dis       Date:  2012-02-15       Impact factor: 5.226

5.  Acute hepatitis C virus infection in a nurse trainee following a needlestick injury.

Authors:  Renzo Scaggiante; Liliana Chemello; Roberto Rinaldi; Giovanni Battista Bartolucci; Andrea Trevisan
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

6.  Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein.

Authors:  Zhenyong Keck; Wenyan Wang; Yong Wang; Patrick Lau; Thomas H R Carlsen; Jannick Prentoe; Jinming Xia; Arvind H Patel; Jens Bukh; Steven K H Foung
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

Review 7.  Immune responses to HCV and other hepatitis viruses.

Authors:  Su-Hyung Park; Barbara Rehermann
Journal:  Immunity       Date:  2014-01-16       Impact factor: 31.745

8.  Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance.

Authors:  Stéphanie B N Serre; Henrik B Krarup; Jens Bukh; Judith M Gottwein
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

9.  Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.

Authors:  Lisa N Wasilewski; Stuart C Ray; Justin R Bailey
Journal:  J Gen Virol       Date:  2016-09-21       Impact factor: 3.891

10.  Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.

Authors:  Rodrigo Velázquez-Moctezuma; Andrea Galli; Mansun Law; Jens Bukh; Jannick Prentoe
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.